电邮这篇文章 Conservative obesity treatment: opportunities and achievements
- 作者: Mkrtumian AM1
-
隶属关系:
- ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
- 期: 卷 15, 编号 6 (2013)
- 页面: 15-20
- 栏目: Articles
- URL: https://ogarev-online.ru/2079-5831/article/view/28252
- ID: 28252
如何引用文章
全文:
详细
Statistics show that 20–25% of the world's population is obese, while 30–50% is just overweight. In order to reduce the risk of cardiovascular disease or its complications it is sufficient to reduce the total body weight by 5–10%. Different substances have high efficiency in limiting the absorption of dietary fat. Clinical studies have shown that the patented complex of natural fibers (litramin IQP G-002AS), obtained from Indian Opuntia (Opuntia ficus-indica) and standardized in point of lipophilic activity reduces absorption of fat contained in food, by binding fat in the gastrointestinal intestinal tract, effectively boosting weight loss.
作者简介
A Mkrtumian
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Email: vagrashot@mail.ru
д-р мед. наук, проф. каф. эндокринологии и диабетологии
参考
- Stevens G, Mascarenhas M, Mathers C. Global health risks: progress and challenges. Bull World Health Organ 2009; 87: 646.
- Мкртумян А.М. Актуальные проблемы консервативного лечения ожирения. Мед. совет. 2010; 7–8: 21–7.
- Bjorntorp P. Obesity. Lancet 1997; 350: 423–6.
- Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385: 1400–04.
- Ожирение. Под ред. И.И.Дедова, Г.А.Мельниченко. М.: Медицинское информационное агентство, 2004.
- Rahmouni K, Correia M.L.G, Haynes W.G et al. Obesity - associated hypertension. Hypertension 2005; 45: 9–14.
- Aronne L.J. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007; 120 (3 Suppl. 1): S26–34.
- Aronne L.J, Segal R.K. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res 2002; 10 (1): 14S–21S.
- Cani P, Amar J, Iglesias M et al. Diabetes 2007; 56: 1761–72.
- Cani P.D, Bibiloni R, Knauf C et al. Diabetes 2008; 57: 1470–81.
- Turnbaugh P, Ridaura V, Faith J et al. Science Translational Medicine 2009; 1: 6–14.
- Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti - obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl._L): L32–8.
- Collazo-Clavell M.L. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255–9; quiz 1259.
- Johansson K, Neovius K, De Santis S.M et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta - analysis. Obes Rev 2009; 10: 564–75.
- US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, 2009; p. 180057.
- Bachmann C. Ein Fasernkomplex zur Gewichts - reduktion undkontrolle. Ars Medici thema Phytotherapie 2010: 25–7.
- Cuellar G.E.M, Ruiz A.M, Monsalve M.C.R et al. Six - month treatment of obesity with sibutramine 15 mg: a double - blind, placebo - controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82.
- Davidson M.H, Hauptman J, Di Girolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42.
- Kahn B.B, Flier J.S. Obesity and insulin resistance. J Clin Invest 2000; 106: 473–81.
补充文件
